Form 8-K Beam Therapeutics Inc. For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)
November 5, 2024 2:56 PM ESTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $48.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst comments "Key updates alongside 3Q results (loss per share of $1.17) centered on the companys SCD/B-thal cell therapy franchise ahead of multiple presentations at... More
Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'
November 5, 2024 11:47 AM ESTStifel analyst Benjamin Burnett reiterated a Buy rating and $69.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM)
The analyst comments "As expected from an initial update from a lead program, early BEAM-101 (sickle cell disease [SCD]) disclosure offers important takeaways that, understandably, trigger investor... More
BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'
November 5, 2024 8:58 AM ESTBMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $57.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst comments "The first-ever clinical data from BEAM's base editing platform in SCD demonstrate a robust BEAM-101 efficacy/safety profile with differentiating characteristics compared... More
